Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?

The endothelial integrity, as mechanical barrier against microorganisms and as natural “anticoagulant”, is crucial for physiologic organ function. Systemic activation of the endothelium upon inflammation, sepsis, and septic shock is always ending in blood–tissue barrier disruption. With increasing dysfunction, uncontrolled clotting activation, capillary microthrombi formation, tissue edema, local hypoxia, and ischemia are initiated. This in turn enhances a vicious circle leading to multiple organ failure and death. Therefore, biomarkers reflecting this special compartment may help in the early detection of systemic inflammation and its complications. This review provides an overview of the most important endothelial biomarkers and their possible use in sepsis.

[1]  A. Janin,et al.  Overexpression of endocan induces tumor formation. , 2003, Cancer research.

[2]  R. Anderson,et al.  Deaths: leading causes for 2001. , 2003, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[3]  M. Dewhirst,et al.  Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. , 1997, Circulation research.

[4]  Alison Fox-Robichaud,et al.  Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis* , 2011, Critical care medicine.

[5]  T. Iba,et al.  [Disseminated intravascular coagulation]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.

[6]  Y. Wang,et al.  Correlation between expression and differentiation of endocan in colorectal cancer. , 2008, World journal of gastroenterology.

[7]  A. Ishizaka,et al.  Soluble form of P-selectin in plasma is elevated in acute lung injury. , 1995, American journal of respiratory and critical care medicine.

[8]  O. Nielsen,et al.  Soluble L-selectin levels predict survival in sepsis , 2002, Intensive Care Medicine.

[9]  M. Gerlach,et al.  L‐selectin in trauma patients: a marker for organ dysfunction and outcome? , 1999, European journal of clinical investigation.

[10]  J. Filep.  Endocan or endothelial cell-specific molecule-1: a novel prognostic marker of sepsis? , 2006, Critical care medicine.

[11]  F. Ballester,et al.  Epidemiology of Sepsis in the Valencian Community (Spain), 1995–2004 , 2008, Infection Control & Hospital Epidemiology.

[12]  J. Vincent,et al.  Implementation of the Surviving Sepsis Campaign guidelines for severe sepsis and septic shock: we could go faster. , 2008, Journal of critical care.

[13]  M. Delehedde,et al.  Loss of Endocan tumorigenic properties after alternative splicing of exon 2 , 2008, BMC Cancer.

[14]  J. Rodríguez-Miguélez,et al.  Serum soluble ICAM-1, VCAM-1, L-selectin, and P-selectin levels as markers of infection and their relation to clinical severity in neonatal sepsis. , 2007, American journal of perinatology.

[15]  Christopher C W Hughes,et al.  Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM. , 2002, Microvascular research.

[16]  S. Lord.  Fibrinogen and fibrin: scaffold proteins in hemostasis , 2007, Current opinion in hematology.

[17]  K. Kaye,et al.  Risk factors for ineffective therapy in patients with bloodstream infection. , 2005, Archives of internal medicine.

[18]  D. Ingber,et al.  Angiopoietin-1 Requires p190 RhoGAP to Protect against Vascular Leakage in Vivo* , 2007, Journal of Biological Chemistry.

[19]  D. Dimitrov,et al.  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.

[20]  A. Mantovani,et al.  Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.

[21]  G. Richards,et al.  The epidemiology of sepsis. , 1973, Clinical orthopaedics and related research.

[22]  T. van der Poll,et al.  Inflammation and coagulation , 2010, Critical care medicine.

[23]  E. B. Smith,et al.  Fate of fibrinogen in human arterial intima. , 1990, Arteriosclerosis.

[24]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[25]  T. van der Poll,et al.  Endothelium: Interface between coagulation and inflammation , 2002, Critical care medicine.

[26]  J. D. De Waele,et al.  Early source control in sepsis , 2010, Langenbeck's Archives of Surgery.

[27]  T. Sawamura,et al.  The processing pathway of endothelin-1 production. , 1998, Journal of cardiovascular pharmacology.

[28]  C. Betsholtz.  Biology of platelet-derived growth factors in development. , 2003, Birth defects research. Part C, Embryo today : reviews.

[29]  T. V. Gopal,et al.  Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. , 1993, Journal of immunology.

[30]  T. Ohmori,et al.  Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. , 2006, Blood.

[31]  L. Mascia,et al.  Leukocyte adhesion molecule profiles and outcome after traumatic brain injury. , 1998, Acta neurochirurgica. Supplement.

[32]  D. Stewart,et al.  Cell-based angiopoietin-1 gene therapy for acute lung injury. , 2007, American journal of respiratory and critical care medicine.

[33]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[34]  H. Zwipp,et al.  Effects of trauma and sepsis on soluble L-selectin and cell surface expression of L-selectin and CD11b. , 1998, The Journal of trauma.

[35]  S. Orfanos,et al.  Angiopoietin-2 is increased in septic shock: evidence for the existence of a circulating factor stimulating its release from human monocytes. , 2009, Immunology letters.

[36]  E. Weitzberg,et al.  Increased concentrations of endothelin-1 messenger RNA in tissues and endothelin-1 peptide in plasma in septic pigs: modulation by betamethasone. , 1996, Critical care medicine.

[37]  T. Ohmori,et al.  Unbalanced expression of ADAMTS13 and von Willebrand factor in mouse endotoxinemia. , 2008, Thrombosis research.

[38]  E. Sage,et al.  PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors , 1994, The Journal of cell biology.

[39]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[40]  C. Sessler,et al.  Soluble E-selectin levels in sepsis and critical illness. Correlation with infection and hemodynamic dysfunction. , 1997, American journal of respiratory and critical care medicine.

[41]  A. Fischer.  Leukocyte adhesion. , 1993, Clinical and experimental rheumatology.

[42]  M. Banach,et al.  Plasma Endothelin-1 Levels in Septic Patients , 2007, Journal of intensive care medicine.

[43]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[44]  N. Christou,et al.  Increased plasma von Willebrand factor in the systemic inflammatory response syndrome is derived from generalized endothelial cell activation. , 1998, Critical care medicine.

[45]  J. Mimuro,et al.  PLASMINOGEN ACTIVATOR INHIBITOR , 1987, Thrombosis and Haemostasis.

[46]  S. Yuan,et al.  Fibrinogen-&ggr; C-Terminal Fragments Induce Endothelial Barrier Dysfunction and Microvascular Leak via Integrin-Mediated and RhoA-Dependent Mechanism , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[47]  D. Hoppensteadt,et al.  Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. , 1998, Clinical chemistry.

[48]  H. Augustin,et al.  Angiopoietins: a link between angiogenesis and inflammation. , 2006, Trends in immunology.

[49]  R. Claus,et al.  The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure? , 2010, Current molecular medicine.

[50]  J. Vincent,et al.  Platelet function in sepsis , 2002, Journal of thrombosis and haemostasis : JTH.

[51]  J. Borkowski,et al.  Soluble selectin profiles associated with severe trauma. , 2001, Archivum immunologiae et therapiae experimentalis.

[52]  J. Tavernier,et al.  ESM-1 Is a Novel Human Endothelial Cell-specific Molecule Expressed in Lung and Regulated by Cytokines* , 1996, The Journal of Biological Chemistry.

[53]  J. Pugin,et al.  Endocan, a new endothelial marker in human sepsis* , 2006, Critical care medicine.

[54]  C. Roussos,et al.  Angiopoietin‐2 is increased in severe sepsis: Correlation with inflammatory mediators , 2007, Critical care medicine.

[55]  D. Stern,et al.  A pathway of coagulation on endothelial cells , 1985, Journal of cellular biochemistry.

[56]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[57]  D. N. Landon,et al.  Angiopoietin-2 is a site-specific factor in differentiation of mouse renal vasculature. , 2000, Journal of the American Society of Nephrology : JASN.

[58]  Derek C. Angus,et al.  Epidemiology of sepsis: An update , 2001, Critical care medicine.

[59]  M. Christ-Crain,et al.  Repeated measurements of endothelin-1 precursor peptides predict the outcome in community-acquired pneumonia , 2011, Intensive Care Medicine.

[60]  F B Taylor,et al.  Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation , 2001, Thrombosis and Haemostasis.

[61]  F. Cohen,et al.  Biochemistry and genetics of von Willebrand factor. , 1998, Annual review of biochemistry.

[62]  Andrius Kazlauskas,et al.  PDGF signaling in cells and mice. , 2004, Cytokine & growth factor reviews.

[63]  Y. Sakata.  Plasminogen activator inhibitor , 1986 .

[64]  R. Doolittle,et al.  Structure of fragment E species from human cross-linked fibrin. , 1981, Biochemistry.

[65]  B. Binder,et al.  Notoginsenoside R1 counteracts endotoxin-induced activation of endothelial cells in vitro and endotoxin-induced lethality in mice in vivo. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[66]  Rolf Rossaint,et al.  Epidemiology of sepsis in Germany: results from a national prospective multicenter study , 2007, Intensive Care Medicine.

[67]  K. Tschaikowsky,et al.  Endothelin in septic patients: Effects on cardiovascular and renal function and its relationship to proinflammatory cytokines , 2000, Critical care medicine.

[68]  P. Knoebl.  Blood coagulation disorders in septic patients , 2010, Wiener Medizinische Wochenschrift.

[69]  C. Betsholtz,et al.  Endothelial-mural cell signaling in vascular development and angiogenesis. , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[70]  Rodger P McEver,et al.  Selectin-carbohydrate interactions during inflammation and metastasis , 1997, Glycoconjugate Journal.

[71]  E. Ruokonen,et al.  Vascular Endothelial Growth Factor in Severe Sepsis and Septic Shock , 2008, Anesthesia and analgesia.

[72]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[73]  H. Lehr,et al.  Microcirculatory dysfunction in sepsis: a pathogenetic basis for therapy? , 2000, The Journal of pathology.

[74]  D. Green,et al.  Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. , 1990, The Journal of clinical investigation.

[75]  M. Trojanowska.  Role of PDGF in fibrotic diseases and systemic sclerosis. , 2008, Rheumatology.

[76]  J. Lafitte,et al.  Endocan Expression and Relationship with Survival in Human Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[77]  Peter Hufnagl,et al.  Plasminogen activator inhibitor 1: physiological and pathophysiological roles. , 2002, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[78]  H Ueno,et al.  The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. , 1992, Science.

[79]  I. Witz.  The selectin–selectin ligand axis in tumor progression , 2008, Cancer and Metastasis Reviews.

[80]  A. Tyagi,et al.  The Microcirculation in Sepsis , 2009, Indian journal of anaesthesia.

[81]  N. Clausell,et al.  Circulating endothelin-1 and tumor necrosis factor-α: early predictors of mortality in patients with septic shock , 2000, Intensive Care Medicine.

[82]  J. A. Russel.  The current management of septic shock. , 2008, Minerva medica.

[83]  S. Opal,et al.  The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. , 2006, The Journal of infectious diseases.

[84]  B. Waaler.  [Vascular permeability]. , 1972, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[85]  B. Löffler,et al.  Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. , 1997, The Biochemical journal.

[86]  Arthur S Slutsky,et al.  Sepsis and endothelial permeability. , 2010, The New England journal of medicine.

[87]  Xiang Ding,et al.  Endocan Expression Correlated with Poor Survival in Human Hepatocellular Carcinoma , 2009, Digestive Diseases and Sciences.

[88]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[89]  M. Pepper,et al.  PDGF‐BB increases endothelial migration and cord movements during angiogenesis in vitro , 1997, Journal of cellular biochemistry.

[90]  J. Struck,et al.  Circulating Precursor Levels of Endothelin-1 and Adrenomedullin, Two Endothelium-Derived, Counteracting Substances, in Sepsis , 2007, Endothelium : journal of endothelial cell research.

[91]  P. Parsons,et al.  Endothelial cell activity varies in patients at risk for the adult respiratory distress syndrome. , 1996, Critical care medicine.

[92]  W. Jiménez,et al.  Plasma endothelin-1 and clinical manifestations of neonatal sepsis , 2004, Journal of perinatal medicine.

[93]  R. Perng,et al.  Plasma soluble vascular endothelial growth factor receptor-1 levels predict outcomes of pneumonia-related septic shock patients: a prospective observational study , 2011, Critical care.

[94]  M. Molyneux,et al.  The role of angiogenic factors in predicting clinical outcome in severe bacterial infection in Malawian children , 2010, Critical care.

[95]  K. Ley.  The role of selectins in inflammation and disease. , 2003, Trends in molecular medicine.

[96]  H. Augustin,et al.  Angiopoietin-1 and Angiopoietin-2 Share the Same Binding Domains in the Tie-2 Receptor Involving the First Ig-like Loop and the Epidermal Growth Factor-like Repeats* , 2003, The Journal of Biological Chemistry.

[97]  N. Semeraro,et al.  Changes in the coagulation-fibrinolysis balance of endothelial cells and mononuclear phagocytes: role in disseminated intravascular coagulation associated with infectious diseases , 1992, International journal of clinical & laboratory research.

[98]  P. Carmeliet,et al.  Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality , 2006, The Journal of experimental medicine.

[99]  V. Meignin,et al.  Characterization of the Secreted Form of Endothelial-Cell-Specific Molecule 1 by Specific Monoclonal Antibodies , 2000, Journal of Vascular Research.

[100]  M. Wellner,et al.  Endothelial Cell Specific Molecule-1 - A Newly Identified Protein in Adipocytes , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[101]  J. Lillehaug,et al.  Structural and functional specificities of PDGF‐C and PDGF‐D, the novel members of the platelet‐derived growth factors family , 2005, The FEBS journal.

[102]  M. Mosesson.  Fibrinogen and fibrin structure and functions , 2005, Journal of thrombosis and haemostasis : JTH.

[103]  M Aguet,et al.  VEGF is required for growth and survival in neonatal mice. , 1999, Development.

[104]  Iain Mackenzie,et al.  Sepsis: definition, epidemiology, and diagnosis , 2007, BMJ : British Medical Journal.

[105]  B. Jude,et al.  Endocan Is a Novel Chondroitin Sulfate/Dermatan Sulfate Proteoglycan That Promotes Hepatocyte Growth Factor/Scatter Factor Mitogenic Activity* , 2001, The Journal of Biological Chemistry.

[106]  G. Remuzzi,et al.  Fluid shear stress modulates surface expression of adhesion molecules by endothelial cells. , 1995, Blood.

[107]  B. Witzenbichler,et al.  Protective Role of Angiopoietin-1 in Endotoxic Shock , 2005, Circulation.

[108]  K. Hirata,et al.  Vascular endothelial cell-derived endothelin-1 mediates vascular inflammation and neointima formation following blood flow cessation. , 2009, Cardiovascular research.

[109]  C. Haslett,et al.  Role of selectiris In development of adult respiratory distress syndrome , 1994, The Lancet.

[110]  R. Kalb,et al.  Angiopoietin-1 Inhibits Endothelial Cell Apoptosis via the Akt/Survivin Pathway* , 2000, The Journal of Biological Chemistry.

[111]  G S Kansas,et al.  Selectins and their ligands: current concepts and controversies. , 1996, Blood.

[112]  M. Nesheim,et al.  The Molecular Weights, Mass Distribution, Chain Composition, and Structure of Soluble Fibrin Degradation Products Released from a Fibrin Clot Perfused with Plasmin* , 1999, The Journal of Biological Chemistry.

[113]  M. Gimbrone,et al.  INTERACTIONS OF PLATELETS AND LEUKOCYTES WITH VASCULAR ENDOTHELIUM: In Vitro STUDIES * , 1982, Annals of the New York Academy of Sciences.

[114]  J. Vincent,et al.  Serial evaluation of the SOFA score to predict outcome in critically ill patients. , 2001, JAMA.

[115]  J. Kimpen,et al.  PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR IN SEVERE SEPSIS , 2005, Shock.

[116]  J. Jais,et al.  Elevated circulating E-selectin, intercellular adhesion molecule 1, and von Willebrand factor in patients with severe infection. , 1998, American journal of respiratory and critical care medicine.

[117]  J. Sunderram,et al.  Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003* , 2007, Critical care medicine.

[118]  M. Borggrefe,et al.  Prognostic value of platelet-derived growth factor in patients with severe sepsis , 2007, Growth factors.

[119]  W. Edwards,et al.  Endothelin in human congestive heart failure. , 1994, Circulation.

[120]  T. Ohmori,et al.  Plasminogen Activator Inhibitor 1 Promotes a Poor Prognosis in Sepsis-Induced Disseminated Intravascular Coagulation , 2006, International journal of hematology.

[121]  L. Toledo-Pereyra,et al.  P-selectin blockade is beneficial after uncontrolled hemorrhagic shock. , 1998, The Journal of trauma.

[122]  H. Hammad,et al.  Human Endothelial-Cell Specific Molecule-1 Binds Directly to the Integrin CD11a/CD18 (LFA-1) and Blocks Binding to Intercellular Adhesion Molecule-11 , 2001, The Journal of Immunology.

[123]  Shogo Fujita,et al.  Vascular Endothelial Growth Factor and Soluble fms‐like Tyrosine Kinase‐1 in Septic Shock Patients Treated With Direct Hemoperfusion With a Polymyxin B‐immobilized Fiber Column , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[124]  K. Wolff,et al.  The fibrin-derived peptide Bβ15–42 protects the myocardium against ischemia-reperfusion injury , 2005, Nature Medicine.

[125]  T. Iba,et al.  ASSOCIATION BETWEEN THE SEVERITY OF SEPSIS AND THE CHANGES IN HEMOSTATIC MOLECULAR MARKERS AND VASCULAR ENDOTHELIAL DAMAGE MARKERS , 2005, Shock.

[126]  M. Christ-Crain,et al.  Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections--hope for hype? , 2009, Swiss medical weekly.

[127]  C. Haslett,et al.  Role of selectins in development of adult respiratory distress syndrome. , 1994, Lancet.

[128]  P. Pickkers,et al.  VASCULAR ENDOTHELIAL GROWTH FACTOR IS INCREASED DURING THE FIRST 48 HOURS OF HUMAN SEPTIC SHOCK AND CORRELATES WITH VASCULAR PERMEABILITY , 2005, Shock.

[129]  M. Wellner,et al.  Adipose tissue and circulating endothelial cell specific molecule-1 in human obesity. , 2006, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[130]  Thomas N. Sato,et al.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.

[131]  L. Languino,et al.  Structural Recognition of a Novel Fibrinogen Chain Sequence (117133) by Intercellular Adhesion Molecule-1 Mediates Leukocyte-Endothelium Interaction (*) , 1995, The Journal of Biological Chemistry.

[132]  J. Struck,et al.  Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia , 2008, BMC infectious diseases.

[133]  F. Taylor,et al.  on be half of the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) , 2001 .

[134]  C. Ince.  The microcirculation unveiled. , 2002, American journal of respiratory and critical care medicine.

[135]  J. Vincent,et al.  Sepsis biomarkers: a review , 2010, Critical care.

[136]  P. Eisenberg,et al.  Elevated concentrations of cross-linked fibrin degradation products in plasma. An early marker of gram-negative bacteremia. , 1993, Chest.

[137]  N. Glazer,et al.  Angiopoietin-1 protects the adult vasculature against plasma leakage , 2000, Nature Medicine.

[138]  L. Borsig,et al.  Selectins promote tumor metastasis. , 2010, Seminars in cancer biology.

[139]  B. Lämmle,et al.  Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. , 2001, Best practice & research. Clinical haematology.

[140]  F. Luscinskas,et al.  Endothelial-Dependent Mechanisms of Leukocyte Recruitment to the Vascular Wall , 2007, Circulation research.

[141]  M. Lyon,et al.  Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. , 2006, Biochimica et biophysica acta.

[142]  Pritpal S Tamber,et al.  The Surviving Sepsis Campaign: raising awareness to reduce mortality , 2003, Critical care.

[143]  T. Carlos,et al.  Leukocyte-endothelial adhesion molecules. , 1994, Blood.

[144]  M. Meisner,et al.  Markers of endothelial damage in organ dysfunction and sepsis , 2002, Critical care medicine.

[145]  S. Wisniewski,et al.  Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 are increased in the plasma of children with sepsis-induced multiple organ failure , 2000, Critical care medicine.

[146]  L. Ngo,et al.  The association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis , 2010, Critical care.

[147]  H. Augustin,et al.  Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation , 2006, Nature Medicine.

[148]  D. Connolly,et al.  Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration , 1990, The Journal of experimental medicine.

[149]  M. Levi.  The coagulant response in sepsis and inflammation , 2010, Hämostaseologie.

[150]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[151]  D. McAuley,et al.  Impaired endothelium-dependent vasodilatation is a novel predictor of mortality in intensive care* , 2011, Critical care medicine.

[152]  K. Jahnz-Różyk,et al.  Epidemiology of sepsis , 2008 .